76 related articles for article (PubMed ID: 30796156)
1. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model.
Walker B; Frytak J; Hayes J; Neubauer M; Robert N; Wilfong L
JAMA Netw Open; 2020 May; 3(5):e205165. PubMed ID: 32421185
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
4. Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.
Accordino MK; Wright JD; Vasan S; Neugut AI; Hillyer GC; Hu JC; Hershman DL
J Clin Oncol; 2016 Aug; 34(24):2820-6. PubMed ID: 27161970
[TBL] [Abstract][Full Text] [Related]
5. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.
Hall PS; Hamilton P; Hulme CT; Meads DM; Jones H; Newsham A; Marti J; Smith AF; Mason H; Velikova G; Ashley L; Wright P
Br J Cancer; 2015 Mar; 112(5):948-56. PubMed ID: 25602964
[TBL] [Abstract][Full Text] [Related]
6. Estimating the cost of caring for people with cancer at the end of life: A modelling study.
Round J; Jones L; Morris S
Palliat Med; 2015 Dec; 29(10):899-907. PubMed ID: 26199134
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the impact of novel metastatic cancer therapies on health inequalities in survival outcomes.
Zebrowska K; Banuelos RC; Rizzo EJ; Belk KW; Schneider G; Degeling K
Front Pharmacol; 2023; 14():1249998. PubMed ID: 38074129
[No Abstract] [Full Text] [Related]
8. Clinical Multiteam System Composition and Complexity Among Newly Diagnosed Early-Stage Breast, Colorectal, and Lung Cancer Patients With Multiple Chronic Conditions: A SEER-Medicare Analysis.
Doose M; Verhoeven D; Sanchez JI; McGee-Avila JK; Chollette V; Weaver SJ
JCO Oncol Pract; 2023 Jan; 19(1):e33-e42. PubMed ID: 36473151
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: findings from a prospective cohort study.
Shaffer VA; Merkle EC; Fagerlin A; Griggs JJ; Langa KM; Iwashyna TJ
Med Care; 2012 Oct; 50(10):849-55. PubMed ID: 22683591
[TBL] [Abstract][Full Text] [Related]
10. Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study.
Voidey A; Pivot X; Woronoff AS; Nallet G; Cals L; Schwetterle F; Limat S
BMC Health Serv Res; 2014 Jul; 14():326. PubMed ID: 25070624
[TBL] [Abstract][Full Text] [Related]
11. Trends in low-value cancer care during the COVID-19 pandemic.
Parikh RB; Civelek Y; Ozluk P; Debono D; Fisch MJ; Sylwestrzak G; Bekelman JE; Schwartz AL
Am J Manag Care; 2024 Apr; 30(4):186-190. PubMed ID: 38603533
[TBL] [Abstract][Full Text] [Related]
12. Deprived social status is associated with decreased use of oral chemotherapy in patients with metastatic colorectal cancer: A retrospective cohort study on administrative databases in a French University Hospital.
Gautier G; Lucas M; Vermeulin T; Di Fiore F; Merle V
Pharmacol Res Perspect; 2021 Dec; 9(6):e00888. PubMed ID: 34766736
[TBL] [Abstract][Full Text] [Related]
13. Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer.
Tan T; Mouradov D; Lee M; Gard G; Hirokawa Y; Li S; Lin C; Li F; Luo H; Wu K; Palmieri M; Leong E; Clarke J; Sakthianandeswaren A; Brasier H; Tie J; Tebbutt NC; Jalali A; Wong R; Burgess AW; Gibbs P; Sieber OM
Cell Rep Med; 2023 Dec; 4(12):101335. PubMed ID: 38118423
[TBL] [Abstract][Full Text] [Related]
14. Identifying and understanding determinants of high healthcare costs for breast cancer: a quantile regression machine learning approach.
Hu L; Li L; Ji J; Sanderson M
BMC Health Serv Res; 2020 Nov; 20(1):1066. PubMed ID: 33228683
[TBL] [Abstract][Full Text] [Related]
15. Population-based trends in systemic therapy use and cost for cancer patients in the last year of life.
Pataky RE; Cheung WY; de Oliveira C; Bremner KE; Chan KK; Hoch JS; Krahn MD; Peacock SJ
Curr Oncol; 2016 Feb; 23(Suppl 1):S32-41. PubMed ID: 26985144
[TBL] [Abstract][Full Text] [Related]
16. How Will a Shift to Value-Based Financial Models Affect Care for Hospitalized Children?
Rappaport DI; Wilding KM; Adkins L; Bourque M; Miller JM
Hosp Pediatr; 2024 Mar; 14(3):e177-e180. PubMed ID: 38351892
[No Abstract] [Full Text] [Related]
17. Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Lam C; Diessner B; Andrade K; Stackland S; Park L; Mehta S; Lin F; Kwong WJ
J Comp Eff Res; 2024 Apr; 13(5):e230166. PubMed ID: 38647165
[No Abstract] [Full Text] [Related]
18. Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022.
Guadamuz JS; Wang X; Ryals CA; Miksad RA; Snider J; Walters J; Calip GS
JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37707536
[TBL] [Abstract][Full Text] [Related]
19. MV-CVIB:
Cui Z; Wu Y; Zhang QH; Wang SG; He Y; Huang DS
Front Microbiol; 2023; 14():1238199. PubMed ID: 37675425
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
